PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that Dr. Steven Steinhubl has joined the Company as Global Vice President, Thrombosis. Dr. Steinhubl will be responsible for the development programs for both cangrelor, an investigational antiplatelet agent, and Angiox® (bivalirudin) from the Company’s European headquarters in Zurich, Switzerland. His appointment marks the Company’s first global leadership position based outside of the United States.
